Eiger Biopharmaceuticals Stock Current Liabilities
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Eiger Biopharmaceuticals fundamentals help investors to digest information that contributes to Eiger Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Eiger Stock. The fundamental analysis module provides a way to measure Eiger Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eiger Biopharmaceutica stock.
Eiger |
Eiger Biopharmaceuticals Company Current Liabilities Analysis
Eiger Biopharmaceutica's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Eiger Biopharmaceutica Current Liabilities | 5.35 M |
Most of Eiger Biopharmaceutica's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eiger Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Eiger Biopharmaceuticals has a Current Liabilities of 5.35 M. This is 99.69% lower than that of the Biotechnology sector and 99.02% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.93% higher than that of the company.
Eiger Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eiger Biopharmaceutica's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eiger Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Eiger Biopharmaceutica by comparing valuation metrics of similar companies.Eiger Biopharmaceutica is currently under evaluation in current liabilities category among its peers.
Eiger Fundamentals
| Return On Equity | -2.26 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (5.28) % | |||
| Current Valuation | 3.88 M | |||
| Shares Outstanding | 1.48 M | |||
| Shares Owned By Insiders | 11.79 % | |||
| Shares Owned By Institutions | 43.86 % | |||
| Number Of Shares Shorted | 29.81 K | |||
| Price To Earning | (2.04) X | |||
| Price To Book | 0.87 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 15.77 M | |||
| Gross Profit | 11.65 M | |||
| EBITDA | (68.74 M) | |||
| Net Income | (74.96 M) | |||
| Cash And Equivalents | 141.79 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 41.2 M | |||
| Debt To Equity | 0.38 % | |||
| Current Ratio | 7.22 X | |||
| Book Value Per Share | (1.08) X | |||
| Cash Flow From Operations | (74.55 M) | |||
| Short Ratio | 3.72 X | |||
| Earnings Per Share | (58.50) X | |||
| Target Price | 30.0 | |||
| Number Of Employees | 56 | |||
| Beta | 1.85 | |||
| Market Capitalization | 2.55 M | |||
| Total Asset | 38.83 M | |||
| Retained Earnings | (512.16 M) | |||
| Working Capital | (15.45 M) | |||
| Current Asset | 57.21 M | |||
| Current Liabilities | 5.35 M | |||
| Net Asset | 38.83 M |
About Eiger Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eiger Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eiger Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eiger Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
Moving against Eiger Stock
| 0.74 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.72 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.68 | WMT | Walmart Aggressive Push | PairCorr |
| 0.65 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.61 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |